JP5777625B2 - 耐酸性カプセル - Google Patents
耐酸性カプセル Download PDFInfo
- Publication number
- JP5777625B2 JP5777625B2 JP2012530383A JP2012530383A JP5777625B2 JP 5777625 B2 JP5777625 B2 JP 5777625B2 JP 2012530383 A JP2012530383 A JP 2012530383A JP 2012530383 A JP2012530383 A JP 2012530383A JP 5777625 B2 JP5777625 B2 JP 5777625B2
- Authority
- JP
- Japan
- Prior art keywords
- water
- capsule
- acid
- gellan gum
- soluble film
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002775 capsule Substances 0.000 title claims description 46
- 239000002253 acid Substances 0.000 title claims description 41
- 239000007902 hard capsule Substances 0.000 claims description 56
- 229920000642 polymer Polymers 0.000 claims description 44
- 229920002148 Gellan gum Polymers 0.000 claims description 40
- 239000000216 gellan gum Substances 0.000 claims description 37
- 235000010492 gellan gum Nutrition 0.000 claims description 37
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 19
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000000126 substance Substances 0.000 claims description 17
- 241001465754 Metazoa Species 0.000 claims description 13
- 230000002496 gastric effect Effects 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 9
- 210000004051 gastric juice Anatomy 0.000 claims description 4
- 239000004014 plasticizer Substances 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 40
- 238000004519 manufacturing process Methods 0.000 description 19
- 238000000034 method Methods 0.000 description 12
- 238000000465 moulding Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000012530 fluid Substances 0.000 description 7
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- 239000003125 aqueous solvent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 5
- 238000007922 dissolution test Methods 0.000 description 5
- 238000007654 immersion Methods 0.000 description 5
- 208000029618 autoimmune pulmonary alveolar proteinosis Diseases 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 238000007598 dipping method Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000001341 hydroxy propyl starch Substances 0.000 description 3
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 239000004373 Pullulan Substances 0.000 description 2
- 229920001218 Pullulan Polymers 0.000 description 2
- 229920001800 Shellac Polymers 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 235000019423 pullulan Nutrition 0.000 description 2
- 239000004208 shellac Substances 0.000 description 2
- 229940113147 shellac Drugs 0.000 description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
- 235000013874 shellac Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229920002444 Exopolysaccharide Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 239000004063 acid-resistant material Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009507 drug disintegration testing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- KHLVKKOJDHCJMG-QDBORUFSSA-L indigo carmine Chemical compound [Na+].[Na+].N/1C2=CC=C(S([O-])(=O)=O)C=C2C(=O)C\1=C1/NC2=CC=C(S(=O)(=O)[O-])C=C2C1=O KHLVKKOJDHCJMG-QDBORUFSSA-L 0.000 description 1
- COHYTHOBJLSHDF-BUHFOSPRSA-N indigo dye Chemical compound N\1C2=CC=CC=C2C(=O)C/1=C1/C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-BUHFOSPRSA-N 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 239000004179 indigotine Substances 0.000 description 1
- 235000012738 indigotine Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000001248 thermal gelation Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C41/00—Shaping by coating a mould, core or other substrate, i.e. by depositing material and stripping-off the shaped article; Apparatus therefor
- B29C41/003—Shaping by coating a mould, core or other substrate, i.e. by depositing material and stripping-off the shaped article; Apparatus therefor characterised by the choice of material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C41/00—Shaping by coating a mould, core or other substrate, i.e. by depositing material and stripping-off the shaped article; Apparatus therefor
- B29C41/02—Shaping by coating a mould, core or other substrate, i.e. by depositing material and stripping-off the shaped article; Apparatus therefor for making articles of definite length, i.e. discrete articles
- B29C41/14—Dipping a core
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29D—PRODUCING PARTICULAR ARTICLES FROM PLASTICS OR FROM SUBSTANCES IN A PLASTIC STATE
- B29D22/00—Producing hollow articles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2001/00—Use of cellulose, modified cellulose or cellulose derivatives, e.g. viscose, as moulding material
- B29K2001/08—Cellulose derivatives
- B29K2001/12—Cellulose acetate
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2003/00—Use of starch or derivatives as moulding material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2005/00—Use of polysaccharides or derivatives as moulding material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2089/00—Use of proteins, e.g. casein, gelatine or derivatives thereof, as moulding material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
- B29L2031/00—Other particular articles
- B29L2031/712—Containers; Packaging elements or accessories, Packages
- B29L2031/7174—Capsules
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
本発明は、新規な耐酸性医薬用硬カプセル、それらの製造方法、及び限定されないが特にヒト又は動物への医薬品、動物用医薬品、食品及び栄養補助食品の経口投与のためのこのようなカプセルの使用に関する。
医薬用硬カプセルは一般に浸漬成形方法を使用して製造される。この方法でピン型(pin molds)を水性ベースのフィルム形成組成物中に浸漬する。続いてピン上に付着した組成物をゲル化させることによりフィルムが形成される。次いでフィルムを乾燥し、ピンから剥離させて所望の長さに切断する。このようにして、充填された医薬用硬カプセルが得られるように後に物質を充填することができて入れ子式に連結され得るカプセルキャップ及び本体が得られる。この方法を開示する特許文献については、例えば特許文献1、特許文献2及び特許文献2を参照することができる。
上記及び他の目的が、(i)水性溶媒、(ii)ジェランガム及び(iii)1つ又はそれ以上の水溶性フィルム形成ポリマーを含むことを特徴とし、該1つ又はそれ以上の水溶性フィルム形成ポリマーに対するジェランガムの質量比が下端及び上端を含めて4/100〜15/100の間である、耐酸性医薬用硬カプセルの製造のための水性組成物により達成される。
(a) 上で定義された水性組成物中にピンを浸漬する工程、
(b) 水性組成物から浸漬ピンを引き揚げる工程、
(c) シェルを得るために浸漬ピンに付着した組成物を乾燥させる工程
を含み;ここで工程(a)〜(c)は、それらが示される順序で行われる。
本発明において、別の指示がなければ、「硬カプセル」はヒト又は動物への経口投与を意図される従来の医薬用硬カプセルを意味し、上記カプセルは、2つの同軸の入れ子式に連結された部分(本体及びキャップと呼ばれる)からなる。通常は、キャップ及び本体は側壁、開口端、及び閉端を有する。これらの部分の各々の側壁の長さは、一般的にカプセル直径より大きい。カプセルのキャップ及び本体は、それらの側壁が部分的に重なって硬カプセルシェルを得るために入れ子式に一緒に連結される。「部分的に重なる」はまた、キャップ及び本体の側壁が実質的に同じ長さを有し、その結果キャップ及び本体が入れ子式に連結されるときにそのキャップの側壁がその本体の側壁全体を包み込む実施態様も包含する。従って、本発明の硬カプセルは、硬カプセルの従来の定義から構造的には逸脱しない。一般に、「カプセル」は空のカプセル及び充填されたカプセルの両方を指すが、一方で「シェル」は特に空のカプセルを指す。硬カプセルシェルが液状形態の物質で充填される場合、本発明の硬カプセルが従来の技術に従って、含有される物質の漏出を避けるために密封されるか又はバンディングされ(banded)得ることが意図される。
a) 上で定義される水性組成物中にピンを浸漬する工程、
b) 水性組成物から浸漬ピンを引き揚げる工程、及び
c) シェルを得るために浸漬ピンに付着した組成物を乾燥させる工程
を含み;
ここで工程(a)〜(c)はそれが示される順序で行われる。
以下の表1は、実施例1〜5において使用される水性組成物の定量的組成を報告する。
医薬用硬カプセルシェルは、以下に開示される(そして全ての実施例について同一の)浸漬成形製造方法にしたがって各組成物から得られた。
容量7.5リットルの反応器において脱イオン水を75℃まで加熱した。粉末形態のジェランガム及びHPMC(2910型、20℃にて2%水溶液で6cPの粘度グレード)を一緒に混合した。次いでこの粉末ブレンドを75℃にて水中に撹拌下で分散させた。ジェランガムが完全に溶解するまで撹拌を続けた。非常に穏やかな撹拌下で溶液を脱泡した後、溶液を60℃で平衡化させた。
工業規模の容器で脱イオン水480リットル中で75℃にてジェランガム5kg及びHPMC 100kg(ジェランガム/HPMC=5/100)から開始したこと以外は実施例1〜5について上で開示された方法にしたがって水性組成物を得た。
実施例6と同じ硬カプセルをパドル(paddle)装置に置き、そして日本薬局方2(JP2)に記載される投薬形態についての溶解試験に従って試験した。カプセルはJP2に開示される人工胃液(pH1.2)及び腸液(pH6.8)を順に使用することにより50rpmで溶解を受けた。溶解試験の結果を図1に報告する。これらの結果は、本発明の硬カプセルの溶解プロフィールがJP2にしたがって腸溶性硬カプセルの定義を満たすということを示す。
Claims (3)
- 耐酸性医薬用硬カプセルであって、本質的に
(i)水分、(ii)ジェランガム、(iii)水溶性フィルムを形成するHPMCポリマー、及び(iv)場合により、不活性で非毒性の医薬品グレード又は食品グレードの顔料、可塑剤、界面活性剤、又は矯味矯臭剤からなる群から選択される少なくとも1つの添加剤からなるシェルを含み、
水溶性フィルムを形成するHPMCポリマーに対するジェランガムの質量比は、下端及び上端を含めて4/100〜15/100の間であり、該カプセルシェルは1つ若しくはそれ以上の酸不安定性物質、及び/又は、ヒト及び/又は動物において胃の副作用と関連する1つ又はそれ以上の物質で充填され、USP−30人工胃液中pH1.2で少なくとも1時間漏出しない、上記耐酸性医薬用硬カプセル。 - ジェランガム及び1つまたはそれ以上の水溶性フィルム形成ポリマーを、1つまたはそれ以上の水溶性フィルム形成ポリマーに対するジェランガムの質量比が、下端及び上端を含めて4/100〜15/100の間で用いる使用であって、1つまたはそれ以上の水溶性フィルム形成ポリマーがHPMCから選択され、医薬用硬カプセルシェル及び医薬用硬カプセルに耐酸性を与えるための上記使用。
- 前記カプセルシェル及びカプセルが、1つ若しくはそれ以上の酸不安定性物質、並びに/又は、ヒト及び/若しくは動物において胃の副作用と関連する1つ若しくはそれ以上の物質で充填される、請求項2に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24539209P | 2009-09-24 | 2009-09-24 | |
US61/245,392 | 2009-09-24 | ||
PCT/IB2010/054131 WO2011036601A1 (en) | 2009-09-24 | 2010-09-14 | Acid resistant capsules |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013505928A JP2013505928A (ja) | 2013-02-21 |
JP2013505928A5 JP2013505928A5 (ja) | 2013-10-31 |
JP5777625B2 true JP5777625B2 (ja) | 2015-09-09 |
Family
ID=43027570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012530383A Active JP5777625B2 (ja) | 2009-09-24 | 2010-09-14 | 耐酸性カプセル |
Country Status (16)
Country | Link |
---|---|
US (4) | US8852631B2 (ja) |
EP (1) | EP2480218B1 (ja) |
JP (1) | JP5777625B2 (ja) |
KR (1) | KR101762460B1 (ja) |
CN (1) | CN102665697B (ja) |
AU (1) | AU2010299527A1 (ja) |
BR (1) | BR112012006651B1 (ja) |
CA (1) | CA2775227C (ja) |
CO (1) | CO6531471A2 (ja) |
DK (1) | DK2480218T3 (ja) |
ES (1) | ES2804779T3 (ja) |
MX (1) | MX2012003540A (ja) |
PL (1) | PL2480218T3 (ja) |
RU (1) | RU2012116362A (ja) |
TW (1) | TW201127370A (ja) |
WO (1) | WO2011036601A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018199631A (ja) * | 2017-05-26 | 2018-12-20 | 株式会社ファンケル | ビフィズス菌含有カプセル製剤 |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2804779T3 (es) | 2009-09-24 | 2021-02-09 | Capsugel Belgium Nv | Cápsulas resistentes a los ácidos |
US20140360404A1 (en) | 2011-11-09 | 2014-12-11 | Capsugel Belgium Nv | Acid resistant banding solution for acid resistant two piece hard capsules |
EP2844297B1 (en) | 2012-05-02 | 2018-08-15 | Capsugel Belgium NV | Aqueous dispersions of controlled release polymers and shells and capsules thereof |
ES2879892T3 (es) * | 2012-05-21 | 2021-11-23 | Capsugel Belgium Nv | Uso de una solución banda resistente a los ácidos para sellar cápsulas duras de dos piezas |
WO2013174884A1 (en) | 2012-05-23 | 2013-11-28 | Capsugel France SAS | Capsules having an incorporated taste modifying component |
JP2014172850A (ja) | 2013-03-07 | 2014-09-22 | Capsugel Belgium Nv | ハードカプセル製剤 |
JP6133702B2 (ja) * | 2013-06-18 | 2017-05-24 | 紀州技研工業株式会社 | インクジェットインキ、その製造方法及びその使用方法 |
WO2015065848A1 (en) | 2013-11-04 | 2015-05-07 | Capsugel Belgium Nv | Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole |
JP6060102B2 (ja) * | 2014-03-13 | 2017-01-11 | 紀州技研工業株式会社 | インクジェットインク及びその作製方法並びにインクジェットインクを用いた印字方法 |
CN103893772B (zh) | 2014-04-21 | 2015-08-26 | 湖南尔康制药股份有限公司 | 一种羟丙基淀粉空心胶囊及其制备工艺 |
CN103937038B (zh) * | 2014-04-28 | 2016-08-17 | 中国科学院化学研究所 | 用于制备空心胶囊的组合物及其淀粉基质空心胶囊 |
EP3181125A4 (en) * | 2014-07-31 | 2018-01-17 | Capsugel Belgium NV | Capsule formulation |
JP6297441B2 (ja) * | 2014-07-31 | 2018-03-20 | 森永乳業株式会社 | ビフィドバクテリウム属細菌含有カプセルおよびその製造方法 |
EP3028694B1 (en) | 2014-12-02 | 2017-07-12 | Capsugel Belgium NV | Dosage form articles for delayed release |
EP3236993B1 (en) | 2014-12-23 | 2023-09-13 | Theriva Biologics, Inc. | Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics |
US20160199433A1 (en) * | 2015-01-13 | 2016-07-14 | New Chapter, Inc. | Vegetarian Capsules Containing Supercritical Herbal Extracts |
EP3566699A1 (en) | 2015-11-10 | 2019-11-13 | Capsugel Belgium NV | Acid resistant banding or sealing solution for acid resistant two piece hard capsules |
US20170157058A1 (en) * | 2015-12-08 | 2017-06-08 | Dah Feng Capsule Industry Co., Ltd. | Acid resistant capsule shell composition, acid resistant capsule shell and its preparing process |
EP3246000A1 (en) | 2016-05-18 | 2017-11-22 | Capsugel Belgium NV | Separable capsule for sprinkling applications |
EP3272340A1 (en) | 2016-07-22 | 2018-01-24 | Capsugel Belgium NV | Acid resistant capsules |
MX2019002265A (es) | 2016-08-24 | 2019-10-30 | Prilenia Therapeutics Dev Ltd | Uso de pridopidina para el tratamiento de la disminucion funcional. |
TWI793141B (zh) | 2017-07-11 | 2023-02-21 | 日商快力膠囊股份有限公司 | 腸溶性硬質膠囊 |
CO2017007322A1 (es) * | 2017-07-24 | 2019-01-31 | Novamed S A | Cápsulas duras resistentes al ácido con bajo contenido de coadyuvantes de gelificacion |
AU2018313766A1 (en) | 2017-08-07 | 2020-02-20 | Finch Therapeutics, Inc. | Compositions and methods for maintaining and restoring a healthy gut barrier |
US11083738B2 (en) | 2017-09-28 | 2021-08-10 | Natals, Inc. | Dietary nutrient compositions |
WO2019139891A1 (en) | 2018-01-09 | 2019-07-18 | Synthetic Biologics, Inc. | Alkaline phosphatase agents for treatment of neurodevelopmental disorders |
JP2021514968A (ja) | 2018-02-23 | 2021-06-17 | フィンチ セラピューティクス ホールディングス エルエルシー | 微生物関連の免疫療法 |
EP4275761A3 (en) | 2018-03-20 | 2024-02-28 | Theriva Biologics, Inc. | Alkaline phosphatase agents for treatment of radiation disorders |
EP3768773A4 (en) * | 2018-03-21 | 2022-11-30 | Selby, Ryan Daniel | VAPORIZER CAPSULES AND METHODS OF MAKING |
EP3549578A1 (en) * | 2018-04-06 | 2019-10-09 | Bio Minerals N.V. | Silicic acid formulation and use thereof |
JP7366893B2 (ja) | 2018-06-22 | 2023-10-23 | クオリカプス株式会社 | 腸溶性硬質カプセル |
EP3632449A1 (en) | 2018-10-05 | 2020-04-08 | Bio Minerals N.V. | Silicic acids for use in the treatment of periodontitis |
KR102182326B1 (ko) | 2019-02-19 | 2020-11-24 | 주식회사 서흥 | 내산성 셀룰로오스 캡슐의 제조방법 |
MX2021010913A (es) * | 2019-03-14 | 2021-10-01 | Evonik Operations Gmbh | Cubierta de capsula que comprende un polimero de nucleo-cubierta y una celulosa. |
CN114502182A (zh) | 2019-07-19 | 2022-05-13 | 芬奇治疗控股有限责任公司 | 用于治疗胃肠道病症的方法及产品 |
AU2020346061A1 (en) | 2019-09-13 | 2022-03-31 | Finch Therapeutics Holdings Llc | Compositions and methods for treating Autism Spectrum Disorder |
CA3153328A1 (en) * | 2019-10-16 | 2021-04-22 | Aouatef Bellamine | Method and composition for increasing muscle protein synthesis |
CA3158132A1 (en) | 2019-10-18 | 2021-04-22 | Finch Therapeutics Holdings Llc | Compositions and methods for delivering a bacterial metabolite to a subject |
WO2021097288A1 (en) | 2019-11-15 | 2021-05-20 | Finch Therapeutics Holdings Llc | Compositions and methods for treating neurodegenerative diseases |
WO2021142347A1 (en) | 2020-01-10 | 2021-07-15 | Finch Therapeutics Holdings Llc | Compositions and methods for non-alcoholic steatohepatitis (nash) |
WO2021142358A1 (en) | 2020-01-10 | 2021-07-15 | Finch Therapeutics Holdings Llc | Compositions and methods for treating hepatic encephalopathy (he) |
TW202140049A (zh) | 2020-01-10 | 2021-11-01 | 美商芬奇治療控股有限責任公司 | 用於治療b型肝炎(hbv)及d型肝炎(hdv)之組合物及方法 |
WO2021202806A1 (en) | 2020-03-31 | 2021-10-07 | Finch Therapeutics Holdings Llc | Compositions comprising non-viable fecal microbiota and methods of use thereof |
IL297885A (en) * | 2020-05-31 | 2023-01-01 | Eirgen Pharma Ltd | Hard capsule dosage form and its uses |
WO2022055993A1 (en) * | 2020-09-08 | 2022-03-17 | The Johns Hopkins University | Method of treatment of irritable bowel syndrome |
WO2022178294A1 (en) | 2021-02-19 | 2022-08-25 | Finch Therapeutics Holdings Llc | Compositions and methods for providing secondary bile acids to a subject |
JPWO2022244713A1 (ja) * | 2021-05-18 | 2022-11-24 | ||
WO2023100643A1 (ja) | 2021-11-30 | 2023-06-08 | クオリカプス株式会社 | 硬質カプセル、硬質カプセルの調製液、及び硬質カプセルの調製方法 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1144225A (en) | 1965-09-07 | 1969-03-05 | Dow Chemical Co | Preparation of medicinal capsule shells from hydroxyalkyl-alkyl cellulose ethers |
US4756902A (en) | 1986-06-02 | 1988-07-12 | Warner-Lambert Company | Capsule sealing process and product |
US5006346A (en) | 1988-04-28 | 1991-04-09 | Alza Corporation | Delivery system |
US5264223A (en) | 1990-03-29 | 1993-11-23 | Japan Elanco Company, Ltd. | Hard capsule for pharmaceutical drugs and method for producing the same |
JP3116602B2 (ja) | 1992-10-06 | 2000-12-11 | シオノギクオリカプス株式会社 | 硬質カプセル |
US5431917A (en) | 1992-10-08 | 1995-07-11 | Japan Elanco Company, Ltd. | Hard capsule for pharmaceutical drugs and method for producing the same |
JPH07196478A (ja) | 1993-12-30 | 1995-08-01 | Hajime Sugii | 安全性の高い食品及び医薬品用ソフトカプセル |
US5756123A (en) | 1994-12-01 | 1998-05-26 | Japan Elanco Co., Ltd. | Capsule shell |
FR2757173A1 (fr) | 1996-12-17 | 1998-06-19 | Warner Lambert Co | Compositions polymeres d'origine non-animale pour la formation de films |
JP4249816B2 (ja) | 1997-02-24 | 2009-04-08 | 富士カプセル株式会社 | ソフトカプセル |
WO1999022769A1 (en) | 1997-10-31 | 1999-05-14 | Monsanto Company | Gellan gum tablet coating |
JP3449253B2 (ja) | 1998-10-29 | 2003-09-22 | シオノギクオリカプス株式会社 | 硬質カプセルの製造方法 |
JP2000212070A (ja) | 1999-01-25 | 2000-08-02 | Su Heung Capsule Co Ltd | 植物性ハ―ド空カプセル及びその製造方法 |
JP3716901B2 (ja) | 1999-04-14 | 2005-11-16 | シオノギクオリカプス株式会社 | セルロースエーテルフィルム |
US6294008B1 (en) | 1999-04-21 | 2001-09-25 | The Dow Chemical Company | Haze-free cellulose ether capsules and process for making |
DE60020716T2 (de) | 1999-07-22 | 2005-12-15 | Warner-Lambert Co. Llc | Filmbildende zusammensetzungen aus pullulan |
KR100379674B1 (ko) | 2000-03-06 | 2003-04-10 | 주식회사 서흥캅셀 | 펙틴과 글리세린의 배합용액을 이용한 셀룰로오스 캅셀 및그의 제조방법 |
GB2366780A (en) | 2000-07-07 | 2002-03-20 | Bioprogress Tech Int Inc | Foam capsules |
EP1184033A1 (en) | 2000-09-01 | 2002-03-06 | Warner-Lambert Company | Pectin film compositions |
JP2002145783A (ja) | 2000-11-06 | 2002-05-22 | Kohjin Co Ltd | S−アデノシルメチオニンまたはその塩類を含有するカプセル製剤 |
US20030072731A1 (en) | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing starch or dextrin |
GB0221986D0 (en) | 2002-09-21 | 2002-10-30 | Bioprogress Technology Ltd | Films with improved barrier properties |
AU2002364498A1 (en) * | 2002-10-22 | 2004-05-13 | Eastgate Investiments Limited | Capsule and film-forming composition comprising gum arabic |
TW200520790A (en) | 2003-12-22 | 2005-07-01 | Dah Feng Capsule Industry Co Ltd | The compositions of a vegetarian capsule shell |
EP1757310A1 (en) | 2004-05-24 | 2007-02-28 | Qualicaps Co., Ltd. | Surface-modified and solubility-improved hard capsule |
WO2006043284A1 (en) | 2004-10-21 | 2006-04-27 | Sunil Mundra | A process for manufacturing neutraceutical, pharmaceutical cellulose derivatives capsule |
JPWO2006070578A1 (ja) | 2004-12-28 | 2008-06-12 | クオリカプス株式会社 | 硬カプセルのバンドシール |
KR100661336B1 (ko) | 2005-02-21 | 2006-12-27 | 주식회사 서흥캅셀 | 기계적 피막강도를 향상시킨 셀룰로오스 경질캅셀 |
WO2006136196A1 (en) * | 2005-06-21 | 2006-12-28 | V. Mane Fils | Gellan seamless breakable capsule and process for manufacturing thereof |
US20070043284A1 (en) | 2005-08-16 | 2007-02-22 | Robert Sanfilippo | Medical electrode and method of use |
EP1762232A1 (en) | 2005-09-09 | 2007-03-14 | Warner-Lambert Company LLC | Liquid filled delivery system, preferably an HPMC capsule filled with glycerol |
WO2007086586A1 (en) * | 2006-01-24 | 2007-08-02 | Qualicaps Co., Ltd. | Low-moisture-content hard capsule and production method therefor |
WO2007098612A1 (en) | 2006-03-02 | 2007-09-07 | Laboratoires Mauves Inc. | Gastric acid resistant gelatin capsule composition and method for producing same |
CA2656540A1 (en) * | 2006-06-30 | 2008-01-10 | Mcneil-Ppc, Inc. | Ibuprofen-containing liquid filled hard capsules |
EP3954715A3 (en) | 2006-10-27 | 2022-05-04 | Capsugel Belgium NV | Hydroxypropyl methyl cellulose hard capsules and process of manufacture |
GB0706178D0 (en) | 2007-03-29 | 2007-05-09 | Univ Aston | Enteric pharmaceutical capsules |
EP2179728A4 (en) | 2007-08-10 | 2013-01-23 | Shanghai Huiyuan Vegetal Capsule Co Ltd | NON-GELATINEOUS ENVELOPE MATERIAL FOR HARD CAPSULE AND PREPARATION METHOD |
EP2223685A4 (en) | 2007-11-13 | 2013-08-21 | Shanghai Huiyuan Vegetal Capsule Co Ltd | HARD-GEL CELLULAR, GASTRORESISTANT AND GELATIN-FREE ENVELOPE AND PROCESS FOR PREPARING THE SAME |
JP5178236B2 (ja) * | 2008-02-25 | 2013-04-10 | クオリカプス株式会社 | 腸溶性カプセル |
US8825387B2 (en) | 2008-07-25 | 2014-09-02 | Navteq B.V. | Positioning open area maps |
JP5253235B2 (ja) * | 2009-03-02 | 2013-07-31 | クオリカプス株式会社 | 腸溶性カプセル |
CA2766202A1 (en) | 2009-06-29 | 2011-01-06 | Mcneil-Ppc, Inc. | Pharmaceutical tablet containing a liquid filled capsule |
MX2012002631A (es) | 2009-09-04 | 2012-04-20 | Capsugel Belgium Nv | Capsulas con aroma. |
ES2804779T3 (es) | 2009-09-24 | 2021-02-09 | Capsugel Belgium Nv | Cápsulas resistentes a los ácidos |
EP2750600B1 (en) | 2011-09-14 | 2017-04-12 | Capsugel Belgium NV | Fill formulations and capsules and method of use to avoid migration of fill into or through the shell |
JP2014172850A (ja) | 2013-03-07 | 2014-09-22 | Capsugel Belgium Nv | ハードカプセル製剤 |
EP3181125A4 (en) | 2014-07-31 | 2018-01-17 | Capsugel Belgium NV | Capsule formulation |
WO2016099921A1 (en) | 2014-12-16 | 2016-06-23 | E. I. Du Pont De Nemours And Company | Films, fluoropolymer coated films and highly cleanable articles |
TWI587880B (zh) | 2015-03-24 | 2017-06-21 | Can be made into the composition of enteric capsule shell, enteric capsule shell and its process | |
US9452141B1 (en) | 2015-05-01 | 2016-09-27 | Dah Feng Capsule Industry Co., Ltd. | Acid resistant capsule shell composition, acid resistant capsule shell and its preparing process |
US20170157058A1 (en) | 2015-12-08 | 2017-06-08 | Dah Feng Capsule Industry Co., Ltd. | Acid resistant capsule shell composition, acid resistant capsule shell and its preparing process |
-
2010
- 2010-09-14 ES ES10759732T patent/ES2804779T3/es active Active
- 2010-09-14 AU AU2010299527A patent/AU2010299527A1/en not_active Abandoned
- 2010-09-14 EP EP10759732.0A patent/EP2480218B1/en active Active
- 2010-09-14 BR BR112012006651-0A patent/BR112012006651B1/pt active IP Right Grant
- 2010-09-14 WO PCT/IB2010/054131 patent/WO2011036601A1/en active Application Filing
- 2010-09-14 CA CA2775227A patent/CA2775227C/en active Active
- 2010-09-14 MX MX2012003540A patent/MX2012003540A/es active IP Right Grant
- 2010-09-14 KR KR1020127010224A patent/KR101762460B1/ko active IP Right Grant
- 2010-09-14 PL PL10759732T patent/PL2480218T3/pl unknown
- 2010-09-14 US US13/497,974 patent/US8852631B2/en active Active
- 2010-09-14 CN CN201080042764.7A patent/CN102665697B/zh active Active
- 2010-09-14 DK DK10759732.0T patent/DK2480218T3/da active
- 2010-09-14 JP JP2012530383A patent/JP5777625B2/ja active Active
- 2010-09-14 RU RU2012116362/15A patent/RU2012116362A/ru not_active Application Discontinuation
- 2010-09-21 TW TW099132015A patent/TW201127370A/zh unknown
-
2012
- 2012-04-25 CO CO12067580A patent/CO6531471A2/es unknown
-
2014
- 2014-08-27 US US14/470,442 patent/US9700517B2/en active Active
-
2017
- 2017-05-04 US US15/587,169 patent/US10231934B2/en active Active
-
2019
- 2019-02-21 US US16/281,817 patent/US10874619B2/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018199631A (ja) * | 2017-05-26 | 2018-12-20 | 株式会社ファンケル | ビフィズス菌含有カプセル製剤 |
Also Published As
Publication number | Publication date |
---|---|
TW201127370A (en) | 2011-08-16 |
US20150050334A1 (en) | 2015-02-19 |
JP2013505928A (ja) | 2013-02-21 |
US10874619B2 (en) | 2020-12-29 |
US20190175514A1 (en) | 2019-06-13 |
EP2480218B1 (en) | 2020-05-27 |
KR101762460B1 (ko) | 2017-07-27 |
ES2804779T3 (es) | 2021-02-09 |
RU2012116362A (ru) | 2013-10-27 |
US9700517B2 (en) | 2017-07-11 |
WO2011036601A1 (en) | 2011-03-31 |
CA2775227A1 (en) | 2011-03-31 |
CN102665697A (zh) | 2012-09-12 |
CN102665697B (zh) | 2014-07-09 |
DK2480218T3 (da) | 2020-08-24 |
EP2480218A1 (en) | 2012-08-01 |
CA2775227C (en) | 2017-12-19 |
KR20120079836A (ko) | 2012-07-13 |
US10231934B2 (en) | 2019-03-19 |
US20170231918A1 (en) | 2017-08-17 |
BR112012006651B1 (pt) | 2021-11-03 |
US20120288562A1 (en) | 2012-11-15 |
PL2480218T3 (pl) | 2020-11-16 |
US8852631B2 (en) | 2014-10-07 |
CO6531471A2 (es) | 2012-09-28 |
BR112012006651A2 (pt) | 2020-08-11 |
AU2010299527A1 (en) | 2012-04-19 |
MX2012003540A (es) | 2012-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5777625B2 (ja) | 耐酸性カプセル | |
JP6626712B2 (ja) | 放出制御ポリマーの水性分散液並びにそのシェル及びカプセル | |
KR101900966B1 (ko) | 벌크한 장용성 캡슐 쉘 | |
WO2000018835A1 (en) | Modified starch film compositions | |
US11904056B2 (en) | Capsule shell comprising a core-shell polymer and a cellulose | |
WO2017080691A1 (en) | Acid resistant banding or sealing solution for acid resistant two piece hard capsules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130909 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130909 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140415 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140421 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140714 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150224 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150520 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150616 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150707 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5777625 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |